Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study

Published:2022-10-07 Issue:1 Volume:200 Page:45-53
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Shragai Tamir¹²^ORCID,Magen Hila²³^ORCID,Lavi Noa⁴⁵^ORCID,Gatt Moshe⁶⁷^ORCID,Trestman Svetlana¹,Zektser Miri⁸,Ganzel Chezi⁷⁹^ORCID,Jarchowsky Osnat²¹⁰,Berger Tamar²¹¹^ORCID,Tadmor Tamar⁵¹²^ORCID,Leiba Merav¹³¹⁴,Hertzog‐Tzarfaty Katrin¹⁵,Horowitz Netanel⁴⁵,Shapira Michael¹⁶,Varssano David²¹⁷,Berger Yoav¹⁸,Frenkel Shahar⁷¹⁹,Krauthammer Mark²¹⁷,Avivi Irit¹²,Luttwak Efrat¹²,Cohen Yael C.¹²^ORCID,

Affiliation:

1. Department of Haematology Tel‐Aviv Sourasky Medical Center Tel‐Aviv Israel

2. Sackler Faculty of Medicine Tel‐Aviv University Tel‐Aviv Israel

3. Department of Haematology Chaim Sheba Medical Center Ramat‐Gan Israel

4. Department of Haematology Rambam Health Care Campus Haifa Israel

5. Faculty of Medicine Technion‐Israel Institute of Technology Haifa Israel

6. Department of Haematology Hadassah Medical Center Jerusalem Israel

7. Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel

8. Department of Haematology Soroka University Medical Center Beer‐Sheva Israel

9. Department of Haematology Shaare Zedek Medical Center Jerusalem Israel

10. Department of Haematology Meir Medical Center Kfar‐Saba Israel

11. Institute of Haematology Davidoff Cancer Center, Rabin Medical Center Petah‐Tikva Israel

12. Department of Haematology Bnai‐Zion Medical Center Haifa Israel

13. Department of Haematology Assuta University Hospital Ashdod Israel

14. Faculty of Health Science Ben‐Gurion University of the Negev Beer‐Sheva Israel

15. Department of Haematology Shamir Medical Center Rishon‐Lezion Israel

16. Department of Haematology Assuta Ramat‐HaHayal Tel‐Aviv Israel

17. Department of Ophthalmology Tel‐Aviv Sourasky Medical Center Tel‐Aviv Israel

18. Department of Ophthalmology Chaim Sheba Medical Center Ramat‐Gan Israel

19. Department of Ophthalmology Hadassah Medical Center Jerusalem Israel

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18479

Reference21 articles.

1. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

2. BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells

3. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

4. Efficacy and safety of Ciltacabtagene Autoleucel (Cilta‐cel), a B‐cell maturation antigen (BCMA)‐directed chimeric antigen receptor (CAR) T‐cell therapy, in lenalidomide‐refractory patients with progressive multiple myeloma after 1‐3 prior lines of therapy: updated results from CARTITUDE‐2;Cohen YC;Blood,2021

5. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin;Oncotarget;2023-12-01

2. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma;Expert Opinion on Drug Safety;2023-11-02

3. Treatment with low‐dose, single‐agent belantamab mafodotin is safe and provides long‐term responses in heavily pretreated multiple myeloma patients;European Journal of Haematology;2023-10-26

4. Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review;Journal of Clinical Medicine;2023-08-25

5. Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial;Cancer;2023-08-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3